Evidence map›Paper›PMID 40436663›Full record

ArticleUltrasound in medicine & biology2025

Feasibility of Contrast-Enhanced Ultrasound Fusion With Pretreatment MR/CT for Recurrence Detection in Renal Cell Carcinoma Patients During Post-Ablation Surveillance.

Aylin Tahmasebi, Tania Siu Xiao, Corinne E Wessner, Cristina M Kuon Yeng Escalante, Andrej Lyshchik, Flemming Forsberg, Ji-Bin Liu, Christopher G Roth, Shuchi K Rodgers, Leann M Kania and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ultrasound in medicine & biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Aylin TahmasebiDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Tania Siu XiaoDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Corinne E WessnerDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Cristina M Kuon Yeng EscalanteDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Andrej LyshchikDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Flemming ForsbergDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Ji-Bin LiuDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Christopher G RothDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Shuchi K RodgersDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA; Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.
Leann M KaniaDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Kevin AntonDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Anju YadavDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Costas D LallasDepartment of Urology, Thomas Jefferson University, Philadelphia, PA, USA.
Stephen R TopperDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.
Edouard J TrabulsiDepartment of Urology, Jefferson Einstein Medical Center, Philadelphia, PA, USA.
John R EisenbreyDepartment of Radiology, Thomas Jefferson University, Philadelphia, PA, USA. Electronic address: john.eisenbrey@jefferson.edu.

Funding

Multi-modality detection of RCC Recurrence Post AblationR01CA269750 · NCI · THOMAS JEFFERSON UNIVERSITY · PI John Eisenbrey, Edouard John Trabulsi · 2023 to 2026
$2.4M
NCI NIH HHS R01 CA269750
6 · The paper itself

Abstract

objectiveContrast enhanced ultrasound (CEUS) is a cost-effective, safe, and accurate modality for monitoring renal cell carcinoma (RCC) recurrence following percutaneous ablation. However, ultrasound delineation of treated tumor borders can be challenging post-ablation. Here, we demonstrate the feasibility of using post-treatment CEUS fused to preablation MR/CT to detect RCC recurrence during long term follow up.

methodsThis study was performed as part of a larger ongoing prospective clinical trial for patients with biopsy-proven RCC treated with percutaneous ablation and receiving contrast enhanced (CE) -CT or -MRI for treatment response monitoring. CEUS with preablation CT/MR fusion was performed within 4 weeks of recurrence screening, and CE-CT/MRI was used as the reference standard. After intravenous injection of an ultrasound contrast agent, CEUS imaging of a single target lesion was performed with ultrasound fused to the patient's pretreatment CT or MRI. RCC recurrence was diagnosed at the bedside based on the presence of iso- to hyper-enhancement within the margins of the ablation cavity compared to normal renal parenchyma.

resultsTo date, 50 participants have been recruited (76% male and 24% female). All participants tolerated the contrast injections without adverse events. CEUS was successfully fused to the participant's pretreatment cross-sectional imaging in all cases and was found to aid in the delineation of the original treatment zone. Additionally, CEUS correlated perfectly (100% agreement) with CE-CT/MRI findings for all the participants.

conclusionPreliminary results demonstrate that post-treatment CEUS fused with a pretreatment CT/MRI is feasible and may aid in the correct localization of the treated tumor margins during long-term post-ablation monitoring.

Indexed as

Carcinoma, Renal CellContrast MediaImage EnhancementKidney NeoplasmsMagnetic Resonance ImagingMultimodal ImagingNeoplasm Recurrence, LocalTomography, X-Ray ComputedAdultAgedFeasibility StudiesFemaleHumansKidneyMaleMiddle AgedContrast MediaContrast agentContrast-enhanced ultrasound—CEUSCryoablationMicrowave ablation, Fusion imagingRenal cell carcinomaSurveillance imagingUltrasound

Identifiers

PMID40436663
PMCPMC12452136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.